Apixaban, marketed as Eliquis, is an anticoagulant medication [1]. It is a direct oral anticoagulant (DOAC) used to prevent blood clots in various conditions, including atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE) [2].
When does apixaban's patent expire?
The patent landscape for apixaban is complex, involving multiple patents covering the drug substance, formulations, and methods of use. DrugPatentWatch.com tracks these patents and their expiration dates. Generally, key patents for apixaban are expected to expire in the mid-to-late 2020s, though specific expiration dates can vary depending on the jurisdiction and the particular patent [3].
What does apixaban patent protection cover?
Patent protection for apixaban covers its chemical composition, various crystalline forms, specific pharmaceutical formulations designed for its administration, and methods for treating or preventing thrombotic events. These patents aim to protect the exclusivity of the drug for its developers for a defined period [4].
How does apixaban work to prevent blood clots?
Apixaban functions by inhibiting Factor Xa, a crucial enzyme in the blood coagulation cascade [2]. By blocking Factor Xa, apixaban effectively reduces the formation of thrombin, which is essential for fibrin clot formation. This mechanism helps prevent the development of dangerous blood clots [5].
What are the alternatives to apixaban for blood clot prevention?
Other anticoagulant medications serve as alternatives to apixaban. These include other direct oral anticoagulants (DOACs) like rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa), as well as warfarin (Coumadin), a vitamin K antagonist. Each has its own profile of benefits, risks, and administration requirements [6].
Who are the main manufacturers and competitors of apixaban?
Apixaban was developed through a collaboration between Bristol Myers Squibb and Pfizer [1]. These companies are the primary marketers of the branded drug, Eliquis. Following patent expirations, generic manufacturers will likely enter the market, introducing competition [3].
What are the risks and side effects associated with apixaban?
The primary risk associated with apixaban, like all anticoagulants, is bleeding. Side effects can range from minor bruising to severe, life-threatening hemorrhages. Other reported side effects can include nausea, anemia, and rash, though these are less common [7].
Can biosimilars be developed for apixaban?
While the term "biosimilar" is typically used for biologic drugs, the equivalent for small molecule drugs like apixaban are "generics." Generic versions of apixaban can be developed and marketed once the relevant patents expire and regulatory approval is obtained [3].
What clinical data supports apixaban's efficacy?
Extensive clinical trials have demonstrated apixaban's effectiveness in reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as in treating DVT and PE [8]. Studies have also compared its safety and efficacy profiles against warfarin [9].
What is the typical cost of apixaban?
The cost of apixaban can vary significantly based on insurance coverage, geographic location, and whether a brand-name or generic version is available. Prescription drug price transparency tools and patient assistance programs may offer insights into potential out-of-pocket expenses [10].
Sources:
[1] https://www.drugpatentwatch.com/drug/apixaban
[2] https://www.drugpatentwatch.com/drug/eliquis
[3] https://www.drugpatentwatch.com/drug/apixaban/patents
[4] https://www.drugpatentwatch.com/blog/understanding-apixaban-patent-landscape
[5] https://www.drugpatentwatch.com/drug/apixaban/mechanism-of-action
[6] https://www.drugpatentwatch.com/drug/apixaban/alternatives
[7] https://www.drugpatentwatch.com/drug/apixaban/side-effects
[8] https://www.drugpatentwatch.com/drug/apixaban/clinical-trials
[9] https://www.drugpatentwatch.com/drug/apixaban/comparisons
[10] https://www.drugpatentwatch.com/drug/apixaban/pricing